Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

111.09 -9.27 (-7.70%)
Streaming Delayed Price Updated: 3:33 PM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Belite Bio, Inc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Belite Bio to Present at the JonesHealthcare Seaside Summit
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Expert Ratings for Belite Bio ↗
 
Via Benzinga
News headline image
Expert Ratings for Belite Bio ↗
 
Via Benzinga
News headline image
BLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024 ↗
BLTE stock results show that Belite Bio missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces $25 Million Registered Direct Offering
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the BTIG Ophthalmology Day
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio, Inc. to present at the Deutsche Bank ADR Virtual Investor Conference on 8 November 2023
Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts
Virtual Investor Conference on November 8th and 9th, 2023 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration... 
Via Benzinga
News headline image
Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results
From Belite Bio, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.